FI885569A0 - Vattenloesliga kamptothecinanaloger. - Google Patents

Vattenloesliga kamptothecinanaloger.

Info

Publication number
FI885569A0
FI885569A0 FI885569A FI885569A FI885569A0 FI 885569 A0 FI885569 A0 FI 885569A0 FI 885569 A FI885569 A FI 885569A FI 885569 A FI885569 A FI 885569A FI 885569 A0 FI885569 A0 FI 885569A0
Authority
FI
Finland
Prior art keywords
alkyl
hydrogen
ch2nh2
formyl
cyano
Prior art date
Application number
FI885569A
Other languages
English (en)
Other versions
FI89923B (fi
FI885569A (fi
FI89923C (fi
Inventor
Jeffrey Charles Boehm
Sidney Michael Hecht
Kenneth George Holden
Randall Keith Johnson
William Dennis Kingsbury
Original Assignee
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beckman Corp filed Critical Smithkline Beckman Corp
Publication of FI885569A0 publication Critical patent/FI885569A0/fi
Publication of FI885569A publication Critical patent/FI885569A/fi
Publication of FI89923B publication Critical patent/FI89923B/fi
Application granted granted Critical
Publication of FI89923C publication Critical patent/FI89923C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Semiconductor Lasers (AREA)
FI885569A 1987-12-01 1988-11-30 Foerfarande foer framstaellning av farmaceutiskt aktiva, vattenloesliga kamptotesinanaloger FI89923C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12714887A 1987-12-01 1987-12-01
US12714887 1987-12-01

Publications (4)

Publication Number Publication Date
FI885569A0 true FI885569A0 (fi) 1988-11-30
FI885569A FI885569A (fi) 1989-06-02
FI89923B FI89923B (fi) 1993-08-31
FI89923C FI89923C (fi) 1993-12-10

Family

ID=22428545

Family Applications (1)

Application Number Title Priority Date Filing Date
FI885569A FI89923C (fi) 1987-12-01 1988-11-30 Foerfarande foer framstaellning av farmaceutiskt aktiva, vattenloesliga kamptotesinanaloger

Country Status (25)

Country Link
US (1) US5004758A (fi)
EP (1) EP0321122B1 (fi)
JP (1) JPH0633268B2 (fi)
KR (1) KR930009357B1 (fi)
CN (3) CN1027265C (fi)
AT (1) ATE143368T1 (fi)
AU (1) AU612735B2 (fi)
CA (1) CA1308102C (fi)
CY (1) CY2017A (fi)
DE (2) DE19775017I2 (fi)
DK (1) DK173034B1 (fi)
ES (1) ES2094721T3 (fi)
FI (1) FI89923C (fi)
GR (1) GR3021990T3 (fi)
HK (1) HK81097A (fi)
IE (1) IE74873B1 (fi)
IL (1) IL88517A (fi)
LU (2) LU90026I2 (fi)
MX (1) MX9203744A (fi)
NL (1) NL970017I2 (fi)
NO (2) NO170487C (fi)
NZ (1) NZ227124A (fi)
PT (1) PT89111B (fi)
SG (1) SG66254A1 (fi)
ZA (1) ZA888938B (fi)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122526A (en) * 1987-03-31 1992-06-16 Research Triangle Institute Camptothecin and analogs thereof and pharmaceutical compositions and method using them
US5106742A (en) * 1987-03-31 1992-04-21 Wall Monroe E Camptothecin analogs as potent inhibitors of topoisomerase I
US5053512A (en) * 1987-04-14 1991-10-01 Research Triangle Institute Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
US5364858A (en) * 1987-03-31 1994-11-15 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5227380A (en) * 1987-03-31 1993-07-13 Research Triangle Institute Pharmaceutical compositions and methods employing camptothecins
US5180722A (en) * 1987-04-14 1993-01-19 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
US5122606A (en) * 1987-04-14 1992-06-16 Research Triangle Institute 10,11-methylenedioxy camptothecins
US5049668A (en) * 1989-09-15 1991-09-17 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin analogs
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
US4939255A (en) * 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
JP2684104B2 (ja) * 1990-02-09 1997-12-03 株式会社ヤクルト本社 新規なカンプトテシン誘導体
DK0547165T3 (da) * 1990-09-28 2000-03-27 Smithkline Beecham Corp Fremgangsmåde til fremstilling af vandopløselige camptothecinanaloger såvel som forbindelserne 10-hydroxy-11-C(1-6)-alkoxyc
US5883255A (en) * 1990-10-31 1999-03-16 Smithkline Beecham Corporation Substituted indolizino 1,2-b!quinolinones
ES2187500T3 (es) * 1991-02-21 2003-06-16 Smithkline Beecham Corp Uso de topotecano en el tratamiento del carcinoma pulmonar no de celulas pequeñas.
WO1992014470A1 (en) * 1991-02-21 1992-09-03 Smithkline Beecham Corporation Treatment of esophageal cancer
ES2349037T3 (es) * 1991-02-21 2010-12-22 Glaxosmithkline Llc Una composición farmacéutica para usar el tratamiento de cáncer de ovario en una persona que lo sufre.
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
DK0540099T3 (da) * 1991-10-29 1996-06-17 Glaxo Wellcome Inc Vandopløselige camptothecinderivater
DK0612248T3 (da) 1991-11-15 2003-12-08 Smithkline Beecham Corp Præparat, der indeholder cisplatin og topotecan som antitumormiddel
EP0661977A1 (en) * 1991-12-10 1995-07-12 Smithkline Beecham Corporation Treatment of colorectal cancer
US6080751A (en) * 1992-01-14 2000-06-27 The Stehlin Foundation For Cancer Research Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
US5446047A (en) * 1992-07-23 1995-08-29 Sloan-Kettering Institute For Cancer Research Camptothecin analogues
US5391745A (en) * 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
JPH08502044A (ja) * 1992-08-21 1996-03-05 デイナ・フアーバー・キヤンサー・インステイテユート ヒトウイルス感染の治療
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5674872A (en) * 1993-08-20 1997-10-07 Smithkline Beecham Corporation Treatment of ovarian cancer
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
AU8052194A (en) * 1993-10-20 1995-05-08 Enzon, Inc. 2'- and/or 7- substituted taxoids
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
GB9402934D0 (en) * 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation
US5468754A (en) * 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
US5597829A (en) * 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5604233A (en) * 1994-04-28 1997-02-18 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
JP4177891B2 (ja) * 1994-04-28 2008-11-05 バイオニューメリック ファーマシューティカルズ インク カンプトテシン又は７−エチルカンプトテシンのラクトン安定処方物
US5491237A (en) * 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US5834442A (en) * 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
US6504029B1 (en) * 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
GB9510716D0 (en) * 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
US5670500A (en) * 1995-05-31 1997-09-23 Smithkline Beecham Corporation Water soluble camptothecin analogs
US5663177A (en) * 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
EP0835303A4 (en) * 1995-06-07 2000-09-13 Univ Jefferson ANTIFUNGAL AGENTS AND THEIR IDENTIFICATION AND UTILIZATION METHODS
AU7732996A (en) * 1995-11-22 1997-06-11 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
US6395541B1 (en) 1996-05-23 2002-05-28 The Rockefeller University Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
AU718799C (en) * 1996-08-19 2004-02-12 Bionumerik Pharmaceuticals, Inc. Highly lipophilic camptothecin derivatives
US6013505A (en) * 1996-10-08 2000-01-11 Smithkline Beecham Corporation Topoisomerase I
US6025156A (en) * 1996-10-15 2000-02-15 Smithkline Beecham Corporation Topoisomerase III
US5962303A (en) * 1996-10-15 1999-10-05 Smithkline Beecham Corporation Topoisomerase III
US6559309B2 (en) 1996-11-01 2003-05-06 Osi Pharmaceuticals, Inc. Preparation of a camptothecin derivative by intramolecular cyclisation
PT1017675E (pt) * 1997-02-14 2006-09-29 Bionumerik Pharmaceuticals Inc Derivados da camtotecina altamente lipofilos
US6207673B1 (en) 1997-03-12 2001-03-27 The University Of North Carolina At Chapel Hill Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
ID23424A (id) 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
US6046209A (en) * 1997-05-27 2000-04-04 Smithkline Beecham Corporation Water soluble camptothecin analogs
KR100289860B1 (ko) * 1997-07-17 2001-05-15 나카무라 하사오 크로만의 제조 방법
US6011042A (en) * 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6214821B1 (en) 1998-03-05 2001-04-10 Washington State University Research Foundation Methods and composition for the inhibition of cancer cells
DK1102594T3 (da) * 1998-08-05 2002-08-26 Aventis Pharma Sa Anvendelse af natriumchlorid til nedsættelse af den gastrointestinale toxicitet af derivater af camptothecin
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
FR2801309B1 (fr) * 1999-11-18 2002-01-04 Adir Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
DK1278518T3 (da) 2000-02-28 2007-01-15 Pfizer Entpr Sarl Synergistisk kombination til behandling af colorektal cancer
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
US6548488B2 (en) 2000-03-17 2003-04-15 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
AR027687A1 (es) * 2000-03-22 2003-04-09 Yakult Honsha Kk Procedimiento para preparar camptotecina
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
KR100742524B1 (ko) 2000-10-27 2007-08-02 아방티 파르마 소시에테 아노님 캄프토테신과 스틸벤 유도체를 포함하는 암 치료용 약제학적 병용제제
US20050003502A1 (en) * 2000-11-14 2005-01-06 Emerald Biostructures, Inc. Structures and methods for designing topoisomerase I inhibitors
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
EA009082B1 (ru) * 2002-03-26 2007-10-26 СиСиАй КОРПОРЕЙШН Агент для улучшения химиотерапии рака
ITRM20020306A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
WO2004055020A1 (en) * 2002-12-16 2004-07-01 Council Of Scientific And Industrial Research Process for the direct preparation of 5-alkoxy and 5-acyloxy analogues of campthothecins or mappicene ketones
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
AU2003223109A1 (en) * 2003-03-31 2004-10-25 Council Of Scientific And Industrial Research Process for preparing topotecan from 10-hydroxy-4-(s) camptothecin
CN100406460C (zh) * 2003-11-10 2008-07-30 中国科学院上海药物研究所 喜树碱的新衍生物、制备方法和用途
TWI333492B (en) * 2003-11-12 2010-11-21 Smithkline Beecham Cork Ltd Crystalline topotecan hydrochloride product and preparation thereof
DE602005027673D1 (de) * 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
JP5170741B2 (ja) 2004-04-27 2013-03-27 ウェルスタット バイオロジクス コーポレイション ウイルスおよびカンプトテシン類を使用する癌の処置
US20050267141A1 (en) 2004-05-28 2005-12-01 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives
US20050272757A1 (en) * 2004-06-04 2005-12-08 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives and novel intermediate and compounds thereof
US7122700B2 (en) * 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
WO2006069344A2 (en) 2004-12-22 2006-06-29 Rutgers, The State University Of New Jersey Controlled release hydrogels
AU2006207321B2 (en) 2005-01-21 2012-09-06 Astex Therapeutics Limited Pharmaceutical compounds
US20090047365A1 (en) * 2005-02-28 2009-02-19 Eisai R & D Management Co., Ltd. Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent
RU2435586C2 (ru) * 2005-07-14 2011-12-10 Веллстат Байолоджикс Корпорейшн Лечение рака с применением вирусов, фторпиримидинов и камптотецинов
WO2007042799A1 (en) * 2005-10-10 2007-04-19 Cipla Limited Novel crystalline forms
WO2007075492A1 (en) * 2005-12-16 2007-07-05 Sonus Pharmaceuticals, Inc. Lipophilic anticancer drug compounds
US7547785B2 (en) 2005-12-26 2009-06-16 Dr. Reddy's Laboratories Limited Process for preparing topotecan
WO2007085370A1 (en) * 2006-01-25 2007-08-02 Heidelberg Pharma Ag 9-(dimethylamino)-methyl-10-hydroxy-camptothecin lipidester derivatives
CN101033230B (zh) * 2006-03-10 2010-12-08 中国科学院上海药物研究所 一类喜树碱衍生物及其应用
JP5313867B2 (ja) 2006-03-30 2013-10-09 ドライス ファーマシューティカルズ，インコーポレイティド カンプトテシン−細胞透過性ペプチド複合体及びそれを含む医薬組成物
WO2007127839A2 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
US20110028536A1 (en) * 2006-08-18 2011-02-03 Gjerset Ruth A Methods and compositions for topoisomerase i modulated tumor suppression
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US7977483B2 (en) * 2007-04-11 2011-07-12 Scinopharm Taiwan, Ltd. Process for making topotecan
US20080255175A1 (en) * 2007-04-16 2008-10-16 Lam Marina K Anti-cancer agents, compositions and methods of treating cancers
JP5315337B2 (ja) * 2007-04-19 2013-10-16 シノファーム タイワン，リミテッド トポテカン塩酸塩の結晶形およびその製造方法
US8026249B2 (en) * 2007-09-14 2011-09-27 Deutena Pharmaceuticals, Inc. Deuterium-enriched topotecan
ITMI20072268A1 (it) 2007-12-04 2009-06-05 Antibioticos Spa Polimorfi cristallini di topotecan cloridrato con elevato grado di purezza e metodi per la loro preparazione
ES2425621T3 (es) * 2008-05-29 2013-10-16 Microbiopharm Japan Co., Ltd. Métodos para producir derivados de camptotecina
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
US8551973B2 (en) * 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
ES2575160T3 (es) 2010-03-15 2016-06-24 The Board Of Trustees Of The University Of Illinois Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
US20140086975A1 (en) 2010-10-15 2014-03-27 Rutgers, The State University Of New Jersey Hydrogel formulation for dermal and ocular delivery
RU2447076C1 (ru) * 2010-12-09 2012-04-10 Закрытое Акционерное Общество "Фарм-Синтез" Способ получения топотекана
EP2654754B1 (en) 2010-12-17 2016-12-21 Novartis AG Combination for treating osteosarcoma, rhabdomyosarcoma and neuroblastoma
US20140371258A1 (en) 2010-12-17 2014-12-18 Nektar Therapeutics Water-Soluble Polymer Conjugates of Topotecan
WO2012087943A2 (en) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
EP2672969A4 (en) 2011-02-01 2014-07-16 Glaxosmithkline Intellectual Property Ltd ASSOCIATION
RS57350B1 (sr) 2011-10-03 2018-08-31 Mx Adjuvac Ab Nanočestice, postupak dobijanja i njihova primena kao nosača amfipatičnih ili hidrofobnih molekula u medicini, uključujući i terapiju kancera, kao i prehrambenih jedinjenja
PL235836B1 (pl) * 2012-10-25 2020-11-02 Inst Chemii Organicznej Polskiej Akademii Nauk Pochodne kamptotecyny, sposób ich otrzymywania i zastosowanie
CN103113381B (zh) * 2013-02-26 2014-12-10 大连理工大学 系列水溶性羟基喜树碱环烷胺醇衍生物及其制法与用途
AR095962A1 (es) 2013-04-01 2015-11-25 Moreinx Ab Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
US10308719B2 (en) 2015-01-26 2019-06-04 The University Of Chicago IL13Rα2 binding agents and use thereof in cancer treatment
WO2016123143A1 (en) 2015-01-26 2016-08-04 The University Of Chicago CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
EP3352796A4 (en) 2015-09-25 2019-05-01 ZY Therapeutics Inc. PARTICLE-BASED MEDICINAL FORMULATION COMPRISING A POLYSACCHARIDE-VITAMIN CONJUGATE
KR102511024B1 (ko) 2016-03-15 2023-03-16 오리존 지노믹스 에스.에이. 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물
BR112018073518A2 (pt) * 2016-05-17 2019-03-19 Scandion Oncology A/S métodos para sensibilização de células de câncer a um tratamento anticâncer, para potencialização do efeito terapêutico de um tratamento anticâncer e para tratamento de câncer, composição, modulador de canais de ânion regulados por volume, kit de peças, e, uso de um modulador de canais de ânion regulados por volume
EP3664844A1 (en) 2017-08-07 2020-06-17 Amgen Inc. Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti pd-l1 antibody and an oncolytic virus
EP3669890A1 (en) 2018-12-18 2020-06-24 Croda International PLC Filamentous nanoparticles having vaccine adjuvant effect
MX2021011330A (es) 2019-03-20 2021-12-10 Univ California Anticuerpos de claudina-6 y conjugados de fármacos.
EP3941944A4 (en) 2019-03-20 2022-11-30 The Regents of the University of California B-SPECIFIC CLAUDIN-6 ANTIBODIES
WO2020210376A1 (en) 2019-04-09 2020-10-15 The Board Of Trustees Of The University Of Illinois Drug adsorbed highly porous activated carbon for enhanced drug delivery
US20220195059A1 (en) 2019-04-30 2022-06-23 Instituto de Medicina Molecular João Lobo Antunes Rank Pathway Inhibitors in Combination with CDK Inhibitors
AU2020303986A1 (en) 2019-06-24 2021-12-09 Amgen Inc. Inhibition of SIRP-gamma for cancer treatment
WO2021043723A1 (en) 2019-09-02 2021-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating pax6- deficiency related disease
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
CN116478174A (zh) * 2022-07-29 2023-07-25 杭州爱科瑞思生物医药有限公司 喜树碱衍生物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
US4342776A (en) * 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4473692A (en) * 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS58134095A (ja) * 1982-02-05 1983-08-10 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
JPS58154582A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS58154584A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd ５位ヒドロキシ置換カンプトテシン誘導体の製造法
JPS5951289A (ja) * 1982-09-17 1984-03-24 Yakult Honsha Co Ltd 新規な９−置換−カンプトテシン誘導体
JPS59227884A (ja) * 1983-06-09 1984-12-21 Yakult Honsha Co Ltd 新規な７−ヒドロキシアルキルカンプトテシン誘導体
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US4775759A (en) * 1984-11-27 1988-10-04 The United States Of America As Represented By The Department Of Health And Human Services Synthesis and utilization of 17-methyl and 17-cyclopropylmethyl-3,14-dihydroxy-4,5α-epoxy 6β-fluoromorphinans (foxy and cyclofoxy) as (18F)-labeled opioid ligands for position emission transaxial tomography (PETT)
US4820816A (en) * 1985-08-02 1989-04-11 President And Fellows Of Harvard College 3-trifuoromethylsulfonyloxy-substituted 1-carbacephalosporins as intermediates for antibiotics
JPH0615546B2 (ja) * 1986-02-24 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
US4894456A (en) * 1987-03-31 1990-01-16 Research Triangle Institute Synthesis of camptothecin and analogs thereof
JP3431931B2 (ja) * 1992-07-16 2003-07-28 旭電化工業株式会社 銅及び銅合金の表面処理方法

Also Published As

Publication number Publication date
FI89923B (fi) 1993-08-31
KR930009357B1 (ko) 1993-09-28
NL970017I1 (nl) 1997-06-02
FI885569A (fi) 1989-06-02
AU2639488A (en) 1989-06-01
SG66254A1 (en) 1999-07-20
GR3021990T3 (en) 1997-03-31
ES2094721T3 (es) 1997-02-01
DE3855575D1 (de) 1996-10-31
CN1083817A (zh) 1994-03-16
CN1035380C (zh) 1997-07-09
NO885352D0 (no) 1988-11-30
IE883576L (en) 1989-06-01
FI89923C (fi) 1993-12-10
IE74873B1 (en) 1997-08-13
NZ227124A (en) 1991-12-23
EP0321122B1 (en) 1996-09-25
JPH01186893A (ja) 1989-07-26
LU90053I2 (fr) 1997-07-01
DK663688D0 (da) 1988-11-28
KR890009934A (ko) 1989-08-05
AU612735B2 (en) 1991-07-18
NL970017I2 (nl) 1997-09-01
IL88517A0 (en) 1989-06-30
DK663688A (da) 1989-06-02
DE3855575T2 (de) 1997-03-20
NO170487C (no) 1992-10-21
US5004758A (en) 1991-04-02
CN1037574C (zh) 1998-03-04
JPH0633268B2 (ja) 1994-05-02
EP0321122A2 (en) 1989-06-21
DE19775017I2 (de) 2002-11-07
LU90026I2 (fr) 1997-04-22
HK81097A (en) 1997-06-20
NO1998003I1 (no) 1998-01-15
MX9203744A (es) 1992-09-01
CY2017A (en) 1998-02-20
ATE143368T1 (de) 1996-10-15
CN1027265C (zh) 1995-01-04
NO170487B (no) 1992-07-13
DK173034B1 (da) 1999-11-29
IL88517A (en) 1994-10-07
PT89111B (pt) 1994-01-31
CA1308102C (en) 1992-09-29
ZA888938B (en) 1990-03-28
CN1087637A (zh) 1994-06-08
EP0321122A3 (en) 1990-12-27
NO885352L (no) 1989-06-02
CN1034724A (zh) 1989-08-16
PT89111A (pt) 1989-12-29

Similar Documents

Publication Publication Date Title
FI885569A0 (fi) Vattenloesliga kamptothecinanaloger.
DE19475017I2 (de) Mevalolacton-Analoga und Derivate Verfahren zur Hetstellung pharmazeutische Zusammenstellungen die sie enthalten und ihre Verwendung als Arzneimittel
NO882608D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrazolopyrideirer.
GR3015850T3 (en) Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process.
MY102689A (en) 4-amino-3-carbonyl substituted quinolines
JO1351B1 (en) Chemical compounds
ES2057126T3 (es) Metodo de tratamiento de la caquexia y algunos nuevos compuestos para utilizar en este metodo.
MY105158A (en) Substituted 4-aminoquinoline derivatives as gastric acid secretion inhibutors.
AU2868689A (en) Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
AU6216886A (en) Substituted 2-cyano-2-phenyl ethyl-amine
EP0186023A3 (en) Biliary acid derivatives, process for their preparation and pharmaceutical compositions containing them
DE3665593D1 (en) Peptide immunostimulants
EP0302633A3 (en) Beta-lactam compound, process for preparing the same, intermediate for synthesis of the same and medicinal composition for bacterially infectious disease therapy containing the same
ES8707939A1 (es) Procedimiento para preparar derivados de n-carboxialquil-2--oxo-3-diaril-5,6-triazinas

Legal Events

Date Code Title Description
BB Publication of examined application
TC Name/ company changed in patent

Owner name: SMITHKLINE BEECHAM CORPORATION

SPCG Supplementary protection certificate granted

Spc suppl protection certif: L108

Extension date: 20111015

FG Patent granted

Owner name: SMITHKLINE BEECHAM CORPORATION

MA Patent expired